Inheart develops an AI-driven digital twin of the heart as a medical device and software platform aimed at improving screening, early detection, and therapeutic support for cardiac disease. The company intends to expand commercially and deploy its solutions across the US, EU, Asia Pacific, and Middle East markets. It plans to use recent funding to develop new software solutions across the cardiac care continuum. Led by CEO Todor Jeliaskov, Inheart emphasizes personalized, predictive therapy to improve decision-making, efficiency of care, and safety of interventions. The announcement notes a USD11M funding round to support these initiatives. The company is based in Pessac, France. inHEART provides a cloud-based software solution that transforms preoperative medical images into a 3D digital twin of the patient’s heart to help plan procedures and assist instrument navigation. The technology is aimed at reducing procedure duration and failure rates during cardiac interventions for arrhythmias. The company plans to use new funding to accelerate commercial development in Europe, access the US market, and continue developing its AI and numerical simulations of cardiac electrical activity. Its technology has been used on more than 2,000 patients in 40 centers worldwide and has been included in the latest international expert recommendations. inHEART is a spin-off from IHU Liryc and Inria and was co-founded by Jean-Marc Peyrat, Prof. Pierre Jaïs, Maxime Sermesant and Hubert Cochet. The company is based in Pessac, France.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

May 2024